Surrozen (SRZN) Amortization of Deferred Charges (2020 - 2026)
Surrozen (SRZN) posted quarterly Amortization of Deferred Charges of $450000.0 for Q1 2026, little changed year-over-year from $451000.0 in Q1 2025, and little changed quarter-over-quarter from $450000.0 in Q4 2025.
Surrozen (SRZN) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Surrozen's Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $450000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges changed 0.22% year-over-year to $450000.0; the TTM figure through Mar 2026 stood at $1.8 million (up 11.39% YoY), while the FY2025 annual figure was $1.8 million, up 18.33% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $450000.0, roughly flat from $450000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $451000.0 in Q1 2025, with the low at $279000.0 in Q3 2022.
- The 5-year median for Amortization of Deferred Charges is $358000.0 (2024), against an average of $374117.6.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges decreased 17.98% in 2023, then surged 33.93% in 2024.
- Surrozen's Amortization of Deferred Charges stood at $290000.0 in 2022, then gained by 15.86% to $336000.0 in 2023, then soared by 33.93% to $450000.0 in 2024, then changed by 0.0% to $450000.0 in 2025, then changed by 0.0% to $450000.0 in 2026.
- Business Quant data shows SRZN's Amortization of Deferred Charges at $450000.0 in Q1 2026, $450000.0 in Q4 2025, and $450000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 450,000.00 |
| Jun 30, 2026 | 450,000.00 |
| Mar 31, 2026 | 450,000.00 |
| Mar 31, 2026 | 450,000.00 |
| Dec 31, 2025 | 450,000.00 |
| Dec 31, 2025 | 450,000.00 |
| Sep 30, 2025 | 450,000.00 |
| Sep 30, 2025 | 450,000.00 |
| Jun 30, 2025 | 450,000.00 |
| Jun 30, 2025 | 450,000.00 |
| Mar 31, 2025 | 451,000.00 |
| Mar 31, 2025 | 451,000.00 |
| Dec 31, 2024 | 450,000.00 |
| Dec 31, 2024 | 450,000.00 |
| Sep 30, 2024 | 358,000.00 |
| Sep 30, 2024 | 358,000.00 |
| Jun 30, 2024 | 357,000.00 |
| Jun 30, 2024 | 357,000.00 |
| Mar 31, 2024 | 357,000.00 |
| Mar 31, 2024 | 357,000.00 |